One Stop Shop For Reports One Stop Shop For Reports
  • All Reports
  • All Sectors
    • Chemicals & Materials
      • Advanced Materials
      • Bulk Chemicals
      • Coatings | Paints and Additives
      • Composites
      • Renewable | Speciality chemicals
    • Consumer Goods
      • Baby Products
      • Consumer Electronics
      • Consumer Packaging
      • Cosmetics & Personal Care
      • Homecare & Decor
      • Luxury & premium products
    • Energy and Power
      • Energy Efficiency and Conservation
      • Green | Renewable Energy
      • Non Renewable | Conventional Energy
      • Power Equipment and Devices
    • Life Science
      • Biotechnology
      • Diagnostics
      • Healthcare
      • Healthcare IT
      • Medical Devices & Supplies
      • Pharmaceuticals
    • Food and Beverage
      • Agriculture & Agri Products
      • Beverages
      • Food Ingredients
      • Food Services and Hospitality
      • Nutraceutical | Wellness Food
      • Processed & Frozen Foods
    • Automotive and Transportation
      • Automotive components
      • Automotive Logistics
      • Automotive systems and accessories
    • Information and Communications Technology
      • E Commerce and Outsourcing
      • Entertainment & Media
      • High Tech | Enterprise & Consumer IT
      • Information & Network Security
      • Mobility | Telecom & Wireless
      • Software and Services
    • Semiconductor and Electronics
      • Semiconductor Materials and Components
      • Display Technology
      • Electronics System and Components
      • Emerging technologies
      • Security and Surveillance
      • Sensors and Controls
    • Building and Construction
      • Construction Materials
      • HVAC
      • Residential Construction and Improvement
      • Roads & Highways
    • Manufacturing
      • Manufacturing Services
      • Heavy Manufacturing
      • Packaging
      • Engineering | Equipment and Machinery
  • Who Trust Us
  • [email protected]
  • +1 718 874 1545 (International)
  • +91 78878 22626 (Asia)

More Results

One Stop Shop For Reports One Stop Shop For Reports
  • All Reports
  • All Sectors
    • Chemicals & Materials
      • Advanced Materials
      • Bulk Chemicals
      • Coatings | Paints and Additives
      • Composites
      • Renewable | Speciality chemicals
    • Consumer Goods
      • Baby Products
      • Consumer Electronics
      • Consumer Packaging
      • Cosmetics & Personal Care
      • Homecare & Decor
      • Luxury & premium products
    • Energy and Power
      • Energy Efficiency and Conservation
      • Green | Renewable Energy
      • Non Renewable | Conventional Energy
      • Power Equipment and Devices
    • Life Science
      • Biotechnology
      • Diagnostics
      • Healthcare
      • Healthcare IT
      • Medical Devices & Supplies
      • Pharmaceuticals
    • Food and Beverage
      • Agriculture & Agri Products
      • Beverages
      • Food Ingredients
      • Food Services and Hospitality
      • Nutraceutical | Wellness Food
      • Processed & Frozen Foods
    • Automotive and Transportation
      • Automotive components
      • Automotive Logistics
      • Automotive systems and accessories
    • Information and Communications Technology
      • E Commerce and Outsourcing
      • Entertainment & Media
      • High Tech | Enterprise & Consumer IT
      • Information & Network Security
      • Mobility | Telecom & Wireless
      • Software and Services
    • Semiconductor and Electronics
      • Semiconductor Materials and Components
      • Display Technology
      • Electronics System and Components
      • Emerging technologies
      • Security and Surveillance
      • Sensors and Controls
    • Building and Construction
      • Construction Materials
      • HVAC
      • Residential Construction and Improvement
      • Roads & Highways
    • Manufacturing
      • Manufacturing Services
      • Heavy Manufacturing
      • Packaging
      • Engineering | Equipment and Machinery
  • Who Trust Us
Home ➤ Life Science ➤ Pharmaceuticals ➤ Orphan Drugs Market
Orphan Drugs Market
Orphan Drugs Market
Published date: Sep 2024 • Formats:
Request Sample Schedule a Call
  • Home ➤ Life Science ➤ Pharmaceuticals ➤ Orphan Drugs Market

Orphan Drugs Market By Therapy (Oncology, Neurology, Endocrinology, Hematology, Cardiovascular, Immunotherapy, Respiratory, and Other Therapies), By Drug Type (Biologics and Non-Biologics), By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, and Online Pharmacy), By Region and Companies - Industry Segment Outlook, Market Assessment, Competition Scenario, Trends, and Forecast 2023-2032

  • Published date: Sep 2024
  • Report ID: 84896
  • Number of Pages: 277
  • Format:
  • Overview
  • Table of Contents
  • Major Market Players
  • Request a Free Sample
  • Quick Navigation

    • Report Overview
    • Key Takeaways
    • Therapy Analysis
    • Drug Type
    • Distribution Channel
    • Key Market Segments
    • Drivers
    • Restraints
    • Opportunity
    • Regional Analysis
    • Key Regions
    • Key Players Analysis
    • Recent Development
    • Report Scope

    Report Overview

    The Orphan Drugs Market size is expected to be worth around USD 477 Billion by 2032 from USD 168 Billion in 2022, growing at a CAGR of 11.3% during the forecast period from 2023 to 2032.

    Pharmaceutical products used to diagnose, prevent, and treat rare medical conditions are referred to as orphan drugs. Due to the fact that they are produced for a selective group of patients, these medications typically have a limited market because they are made to meet a specific public health requirement. It is anticipated that this market’s expansion will also be aided by an increase in healthcare spending and the prevalence of rare diseases. Orphan drug market expansion is also anticipated to be driven by favorable government regulations and reimbursement rules.

    Orphan Drugs Market Value

    Key Takeaways

    • Market Growth: The orphan drugs market to reach USD 477 Bn by 2032, growing at 11.3% CAGR from 2023.
    • Therapy Dominance: Oncology leads in revenue share due to the rising demand for cancer treatments.
    • Biologics Lead: Biological orphan drugs are the market leaders, driven by effectiveness and fewer side effects.
    • Distribution Channels: Hospital pharmacies hold the majority due to intravenous medication administration. Online pharmacies and retail are growing.
    • Market Drivers: Growth fueled by rare disease prevalence, demand for immunomodulators, and favorable regulations.
    • Market Restraints: High treatment costs, strict regulations, and a lack of awareness pose challenges.
    • Opportunities: Increasing rare disease cases creates growth opportunities, aided by FDA incentives and funding.
    • Regional Analysis: North America dominates due to favorable policies; Europe and Asia-Pacific show growth potential.

    Therapy Analysis

    The oncology segment is accounted to hold a significant revenue share and dominate the orphan drugs market

    Based on therapy, the global orphan drugs market outlook is segmented into oncology, neurology, endocrinology, hematology, cardiovascular, immunotherapy, respiratory, and other Therapies. Among these therapies, the oncology segment is predicted to hold the largest revenue share.

    Interest in the sector is expected to rise as more leisure activities become available. The drug division that deals with oncology treats an increasing number of cancer patients with various diseases each year. In the field of drug development, there is a growing demand and interest in powerful medications to combat the situation. As a consequence of this, it is anticipated that the global market for orphan drugs will experience development opportunities in the coming years.

    The development of effective medications to treat or maintain control of chronic conditions is necessary due to the rising geriatric rate of the elderly population. Interest in the industry has increased as a result of significant growth in the global orphan drug market over the forecast period.

    Drug Type

    The biologics segment is the most lucrative and holds the largest share of this market

    Based on the drug, the global orphan drug market is divided into biologics and non-biologicals. The biological orphan drugs segment holds the largest share of the market and is anticipated to expand at a faster rate during the forecast period.

    The current trend of biological orphan drug approval for a variety of applications has led to expansion and has inspired both existing and new market players to arrive in this sector. Rare diseases have long been treated with biological medicines. Despite its higher prevalence in developed nations, cancer, a most targeted orphan disease, has been successfully treated by biological therapies with less side effects.

    Distribution Channel

    Hospital Pharmacies dominate the market and are expected to remain dominant over the forecast period

    Based on distribution channel, the global orphan drugs market is divided into hospital pharmacy, retail pharmacy, and online pharmacy. It is anticipated that hospital pharmacies will hold the majority of the market. This is because skilled healthcare providers in hospitals are required to administer a significant amount of medications intravenously. The Retail pharmacy segment is anticipated to expand at a moderate CAGR over the anticipated time frame, and this will largely contribute to the orphan drugs market growth.

    In the coming years, online pharmacy will complement the shifting of market dynamics. This growth can be attributed to the ease of use of the platform by customers when purchasing medications. Additionally, the online pharmacy industry has grown significantly as a result of the growing number of COVID-19-infected customers turning to online pharmacies to purchase medications.
    Orphan Drugs Market

    Key Market Segments

    By Therapy

    • Oncology
    • Neurology
    • Endocrinology
    • Hematology
    • Cardiovascular
    • Immunotherapy
    • Respiratory
    • Other Therapies

    By Drug Type

    • Biologics
    • Non-Biologics

    By Distribution Channel

    • Hospital Pharmacy
    • Retail Pharmacy
    • Online Pharmacy

    Drivers

    Rising cases of rare diseases are projected to the expansion of the orphan drugs market

    Treatments for rare diseases frequently require a cold chain, which is a temperature-controlled supply chain that is not readily accessible in all nations. Rare or orphan diseases only affect 7 out of every 10,000 people. However, rare diseases’ global prevalence has been rising in recent years. In January 2022, there will be approximately 54,500 new cases of oropharyngeal or oral cancer in the United States, according to an article that was shared by the American Cancer Society. 11,250 people are affected by oral (oropharyngeal) cancer.

    These cancers can strike at any age, but the average age at diagnosis is 60-65. One in five of all cases involves patients under the age of 55 or slightly more than 20%. As a result, the market for orphan drugs is expanding in response to the rising incidence of diseases.

    Increasing demand for immunomodulators and favorable government regulations are subject to boost the market growth

    Market expansion will be driven by rising demand for immunomodulators, which regulate or enhance the immune system. The orphan drug market is expected to grow during the forecast period as a result of the rising incidence of infectious diseases in developed and developing nations as well as rising drug costs.

    Favorable government regulations are driving growth in the market for orphan pharmaceuticals. The industry’s growth is also aided by the possibility of orphan medication manufacturers holding exclusive commercial rights.

    Restraints

    Higher Costs of Treatment and strict regulations are restraining the market growth

    High per-patient treatment costs and regulatory restrictions on profitability may also pose a challenge to the market’s growth during the forecast period, as well as a lack of awareness among patients and physicians regarding the treatment of orphan diseases and the high costs associated with these drug developments.

    Opportunity

    An increase in the prevalence of rare diseases generates higher opportunities in the market

    Around 300 million people worldwide are anticipated to be affected by recurrent, rare, and chronic illnesses, as well as increased demand for significant amounts of orphan drug production.

    Medicines for rare diseases like yellow fever, Waardenburg syndrome, von Willebrand disease, abetalipoproteinemia, diabetic macular edema, yellow nail syndrome, autism spectrum disorder (ASD), and von Hippel-Lindau syndrome, among others, are in high demand, which helps expand the market.

    In addition, the FDA provides free exemptions, favorable reimbursement policies, public R&D grants, and premium pricing to help businesses expand.

    Regional Analysis

    North America accounted for the highest revenue share of the global orphan drugs market

    Based on region, the global orphan drugs market is divided into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America accounted for dominating the market with the largest revenue share. The promotion of laws that enable the rapid approval of such drugs, drug status exclusivity for such drugs, and a robust health system all contribute to the industry’s expansion.

    Regional development is being sped up by key players, a well-established healthcare network, and a growing number of patients. Additionally, regional development is being aided by favorable government funding and policies. In the United States, orphan drugs receive tax breaks and a user fee waiver in addition to 7 years of marketing exclusiveness following FDA approval for a specific use.

    The European market is anticipated to expand quickly due to the region’s large patient population and wide-ranging acceptance of cutting-edge treatments for rare diseases. North America dominates the market because of this and the favorable reimbursement policies in the United States.

    Due to increasing healthcare costs and heightened awareness of rare diseases, the Asia-Pacific market is anticipated to expand at the fastest rate. The Asia-Pacific orphan drugs market is expected to expand as the prevalence of rare diseases rises, and people become more aware of them.

    Additionally, Asia-Pacific clinical trial expansion is anticipated to be more rapid than that in Europe and the United States, driving regional expansion. Orphan drug availability should rise in developing regions as a result of government initiatives to expand community health and oncology centers.

    Orphan Drugs Market Region

    Key Regions

    North America

    • The US
    • Canada

    Western Europe

    • Germany
    • France
    • The UK
    • Spain
    • Italy
    • Portugal
    • Ireland
    • Austria
    • Switzerland
    • Benelux
    • Nordic
    • Rest of Western Europe

    Eastern Europe

    • Russia
    • Poland
    • The Czech Republic
    • Greece
    • Rest of Eastern Europe

    APAC

    • China
    • Japan
    • South Korea
    • India
    • Australia & New Zealand
    • Indonesia
    • Malaysia
    • Philippines
    • Singapore
    • Thailand
    • Vietnam
    • Rest of APAC

    Latin America

    • Brazil
    • Colombia
    • Chile
    • Argentina
    • Mexico
    • Costa Rica
    • Rest of Latin America

    Middle East & Africa

    • Algeria
    • Egypt
    • Israel
    • Kuwait
    • Nigeria
    • Saudi Arabia
    • South Africa
    • Turkey
    • United Arab Emirates
    • Rest of MEA

    Key Players Analysis

    The market for orphan drugs is somewhat competitive. The market is currently dominated by a small number of major players in terms of orphan disease market share. A few smaller players are entering the market and now hold a significant share due to the rising number of diseases and cases each year.

    Moreover, they are involved in partnerships, acquisitions, collaborations, mergers, and new product launches. This forms the competitive landscape among the key market players

    Market Key Players

    Listed below are some of the prominent orphan drugs market companies that form a competitive landscape in the global orphan drug market.

    • Hoffmann-La Roche Ltd. (Switzerland)
    • Novartis AG (Switzerland)
    • Johnson & Johnson Services Inc. (U.S.)
    • Merck KGaA (Germany)
    • Bristol-Myers Squibb Company (U.S.)
    • Pfizer Inc. (U.S.)
    • Eli Lilly and Company (U.S.)
    • Novo Nordisk A/S (Denmark)
    • Takeda Pharmaceutical Company Limited (Japan)
    • Alexion Pharmaceuticals, Inc. (U.S.)
    • Kyowa Kirin Co., Ltd. (Japan)
    • GlaxoSmithKline Plc
    • AbbVie Inc.
    • Sanofi S.A
    • Amgen Inc. (U.S.)
    • Biogen Inc. (U.S.)
    • Celldex Therapeutics (U.S.)
    • GSK plc. (U.K.)
    • Eisai Co., Ltd. (Japan)
    • Vertex Pharmaceuticals Incorporated (U.S.)
    • Alexion Pharmaceutical Inc.
    • ALX Oncology Holdings Inc.
    • BioMarin Pharmaceutical Inc.
    • Agios Pharmaceuticals Inc.
    • DAIICHI SANKYO Company Ltd.
    • Other Key Players

    Recent Development

    • In March 2022, CER-001, which was developed by ABIONYX Pharma, was granted FDA approval for Orphan Drugs Designation (ODD) for the diagnosis of LCAT deficiency that manifests as kidney dysfunction or ophthalmologic illness. Both partial LCAT insufficiency, which causes Fisheye Disease, and comprehensive LCAT deficiency, which causes renal symptoms and corneal opacities, are referred to by this term. The progression of LCAT deficiency, for which there is no treatment, can eventually result in kidney disease that calls for kidney transplantation or dialysis and/or corneal opacification that calls for a transplant.
    • In April 2022, Shanghai Henlius Biotech revealed in a press release that the Food and Drug Administration has granted serplulimab, also known as Hansizhuang, orphan drug status for the treatment of SCLC, or small cell lung cancer.
    • In February 2022, The European Commission granted AZP-3601 Orphan Drug Designation (ODD) for the treatment of hypoparathyroidism, according to Amolyt Pharma, a multinational corporation that focuses on developing therapeutic peptides for rare endocrine and associated conditions. ODD grants sponsors access to centralized marketing authorization, funding for the proposed, reduced regulatory costs, and ten years of market exclusiveness if granted.

    Report Scope

    Report Features Description
    Market Value (2022) USD 168 Billion
    Forecast Revenue (2032) USD  477 Billion
    CAGR (2023-2032) 11.3%
    Base Year for Estimation 2022
    Historic Period 2016-2022
    Forecast Period 2023-2032
    Report Coverage Revenue Forecast, Market Dynamics, COVID-19 Impact, Competitive Landscape, Recent Developments
    Segments Covered By Therapy – Oncology, Neurology, Endocrinology, Hematology, Cardiovascular, Immunotherapy, Respiratory, and Other Therapies; By Drug Type – Biologics and Non-Biologics; By Distribution Channel – Hospital Pharmacy, Retail Pharmacy, and Online Pharmacy
    Regional Analysis North America – The US, Canada, & Mexico; Western Europe – Germany, France, The UK, Spain, Italy, Portugal, Ireland, Austria, Switzerland, Benelux, Nordic, & Rest of Western Europe; Eastern Europe – Russia, Poland, The Czech Republic, Greece, & Rest of Eastern Europe; APAC – China, Japan, South Korea, India, Australia & New Zealand, Indonesia, Malaysia, Philippines, Singapore, Thailand, Vietnam, & Rest of APAC; Latin America – Brazil, Colombia, Chile, Argentina, Costa Rica, & Rest of Latin America; Middle East & Africa – Algeria, Egypt, Israel, Kuwait, Nigeria, Saudi Arabia, South Africa, Turkey, United Arab Emirates, & Rest of MEA
    Competitive Landscape F. Hoffmann-La Roche Ltd. (Switzerland), Novartis AG (Switzerland), Johnson & Johnson Services Inc. (U.S.), Merck KGaA (Germany), Bristol-Myers Squibb Company (U.S.), Pfizer Inc. (U.S.), Eli Lilly and Company (U.S.), Novo Nordisk A/S (Denmark), Takeda Pharmaceutical Company Limited (Japan), Alexion Pharmaceuticals, Inc. (U.S.), Kyowa Kirin Co., Ltd. (Japan), GlaxoSmithKline Plc, AbbVie Inc., Sanofi S.A, Amgen Inc. (U.S.), Biogen Inc. (U.S.), Celldex Therapeutics (U.S.), GSK plc. (U.K.), Eisai Co., Ltd. (Japan), Vertex Pharmaceuticals Incorporated (U.S.), Alexion Pharmaceutical Inc., ALX Oncology Holdings Inc., BioMarin Pharmaceutical Inc., Agios Pharmaceuticals Inc., DAIICHI SANKYO Company Ltd.
    Customization Scope Customization for segments, region/country-level will be provided. Moreover, additional customization can be done based on the requirements.
    Purchase Options We have three licenses to opt for: Single User License, Multi-User License (Up to 5 Users), Corporate Use License (Unlimited User and Printable PDF)
    Orphan Drugs Market
    Orphan Drugs Market
    Published date: Sep 2024
    add_shopping_cartBuy Now get_appDownload Sample
    keyboard_arrow_up
    • Hoffmann-La Roche Ltd. (Switzerland)
    • Novartis AG (Switzerland)
    • Johnson & Johnson Services Inc. (U.S.)
    • Merck KGaA (Germany)
    • Bristol-Myers Squibb Company (U.S.)
    • Pfizer Inc. (U.S.)
    • Eli Lilly and Company (U.S.)
    • Novo Nordisk A/S (Denmark)
    • Takeda Pharmaceutical Company Limited (Japan)
    • Alexion Pharmaceuticals, Inc. (U.S.)
    • Kyowa Kirin Co., Ltd. (Japan)
    • GlaxoSmithKline Plc
    • AbbVie Inc. Company Profile
    • Sanofi S.A
    • Amgen Inc. (U.S.)
    • Biogen Inc. (U.S.)
    • Celldex Therapeutics (U.S.)
    • GSK plc. (U.K.)
    • Eisai Co., Ltd. (Japan)
    • Vertex Pharmaceuticals Incorporated (U.S.)
    • Alexion Pharmaceutical Inc.
    • ALX Oncology Holdings Inc.
    • BioMarin Pharmaceutical Inc.
    • Agios Pharmaceuticals Inc.
    • DAIICHI SANKYO Company Ltd.
    • Other Key Players
  • settingsSettings

Related Reports

  • Rare Disease Genetic Testing Market
  • Precision Medicine Market
  • Precision Oncology Market
  • Predictive & Personalized Medicine Market
  • Autoimmune Disease Diagnostics Market

Our Clients

  • Our Clients
Inquiry Before Buying

Orphan Drugs Market
  • 84896
  • Sep 2024
    • ★★★★★
      ★★★★★
    • (105)
add_shopping_cart Buy Now
Trusted by more than 17382 organizations globally
  • Client Logo
  • Client Logo
  • Client Logo
✖
Request a Sample Report
We'll get back to you as quickly as possible

Single User
$6,000
$3,999
USD / per unit
save 24%
Multi User
$8,000
$5,999
USD / per unit
save 28%
Corporate User
$10,000
$6,999
USD / per unit
save 32%
e-Access
Report Library Access
Data Set (Excel)
Print
Company Profile Library Access
Interactive Dashboard
Free Custumization No up to 10 hrs work up to 30 hrs work
Accessibility 1 User 2-5 User Unlimited
Analyst Support up to 20 hrs up to 40 hrs up to 50 hrs
Benefit Up to 20% off on next purchase Up to 25% off on next purchase Up to 30% off on next purchase
Buy Now ($ 3,999) Buy Now ($ 5,999) Buy Now ($ 6,999)
  • location_on420 Lexington Avenue, Suite 300 New York City, NY 10170,
    United States
  • phone+1 718 874 1545 (International)
  • phone+91 78878 22626 (Asia)
  • email[email protected]
  • Facebook Logo
  • Twitter Logo
  • LinkedIn Logo
Find Help
  • Contact Us
  • How to Order
Legal
  • Privacy Policy
  • Refund Policy
  • Frequently Asked Questions
  • Terms and Conditions
Explore
  • About Us
  • All Reports
  • All Sectors
  • Infographics
  • Statistics and Facts
  • Companies
Secured Payment Options
Secured Payment Options

© 2025 Market.Us. All Rights Reserved.